Efficacy and safety of long-term tolvaptan treatment in a patient with SCLC and SIADH.

Abstract

Hyponatremia frequently occurs in patients with cancer and is mostly due to a syndrome of inappropriate antidiuresis caused by ectopic secretion of antidiuretic hormone (SIADH). Small cell lung cancer presents with SIADH in approximately 11%-15% of cases. Recently, a new class of drugs, vasopressin V2-receptor antagonists (vaptans), emerged as a promising treatment for SIADH, but efficacy and safety data in cancer patients are lacking. We present a case of SIADH, heralding small cell lung cancer and persisting after apparent complete remission of primary tumor following chemotherapy/radiotherapy, in a patient who underwent long-term treatment with tolvaptan without any serious adverse effects.

• Authors: Paola Bordi, Marcello Tiseo, Sebastiano Buti, Giuseppe Regolisti, Andrea Ardizzoni
• Journal: Tumori (Tumori) Vol. 101 Issue 2 Pg. e51-3 (Apr 28 2015) ISSN: 2038-2529 [Electronic] United States
• PMID: 25702667 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antidiuretic Hormone Receptor Antagonists
• Benzazepines
• Tolvaptan

Topics

• Antidiuretic Hormone Receptor Antagonists (administration & dosage, adverse effects, therapeutic use)
• Benzazepines (administration & dosage, adverse effects, therapeutic use)
• Chemoradiotherapy
• Drug Administration Schedule
• Female
• Humans
• Hyponatremia (drug therapy, etiology, prevention & control)
• Inappropriate ADH Syndrome (complications, drug therapy, etiology)
• Lung Neoplasms (complications, metabolism, therapy)
• Middle Aged
• Remission Induction
• Small Cell Lung Carcinoma (complications, metabolism, therapy)
• Tolvaptan
• Treatment Outcome